The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy/safety of epacadostat plus pembrolizumab in triple-negative breast cancer and ovarian cancer: Phase I/II ECHO-202 study.
 
Alexander I. Spira
Honoraria - ARIAD; Clovis Oncology; Novartis; Roche
Consulting or Advisory Role - ARIAD; Clovis Oncology; Roche/Genentech
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Ignyta (Inst); Incyte (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novartis (Inst); Roche (Inst)
Expert Testimony - Novartis
Travel, Accommodations, Expenses - ARIAD; Clovis Oncology; Roche
 
Omid Hamid
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Novartis; Roche
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Genentech; Novartis
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Genentech (Inst); Immunocore (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Rinat (Inst); Roche (Inst)
 
Todd Michael Bauer
Employment - Sarah Cannon Research Institute; Tennessee Oncology
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Calithera Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immunogen (Inst); Incyte (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); MabVax (Inst); MedImmune (Inst); medpacto (Inst); Merck (Inst); Merrimack (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Principa Biopharma (Inst); Stemline Therapeutics (Inst)
 
Virginia F. Borges
Research Funding - Abbott/AbbVie (Inst); Advaxis (Inst); Galena Biopharma (Inst); Incyte (Inst); Merrimack (Inst); Oncothyreon (Inst)
 
Jeffrey S. Wasser
Stock and Other Ownership Interests - Biogen; Bristol-Myers Squibb; Johnson & Johnson; Lilly; Merck (I); Pfizer (I)
Consulting or Advisory Role - Amgen; Novartis
Research Funding - Amgen; Incyte; Pfizer
Travel, Accommodations, Expenses - Amgen
 
David C. Smith
Research Funding - Agensys (Inst); Atterocor (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb/Medarex (Inst); Celgene (Inst); ESSA (Inst); Exelixis (Inst); Genentech (Inst); ImClone Systems (Inst); Incyte (Inst); Lilly (Inst); MedImmune (Inst); Medivation/Astellas (Inst); Millennium (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Regeneron (Inst); Seagen (Inst); Takeda (Inst); Tekmira (Inst); Teva (Inst)
 
Amy Sanders Clark
Consulting or Advisory Role - Novartis
 
Emmett V. Schmidt
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Yufan Zhao
Employment - Amgen (I); Incyte
Stock and Other Ownership Interests - Amgen (I); Incyte
Travel, Accommodations, Expenses - Amgen (I); Incyte
 
Janet E. Maleski
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Tara C. Gangadhar
Honoraria - Medscape
Research Funding - Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst)